How to optimize current treatment of genotype 2 hepatitis C virus infection

The standard of care (SOC) for hepatitis C virus (HCV) genotype 2 is pegylated interferon (PEG‐IFN) plus ribavirin (RBV). Even though most patients can be cured with this therapy after 24 weeks, tailoring treatment can improve its safety and efficacy in special populations. Thus, shortening treatment together with a weight‐based RBV dosing approach has been considered satisfactory in patients with positive predictors of response. With the development of the direct antiviral agents (DAAs), shorter, better tolerated and more efficient treatments for HCV genotype 2 will become available, including interferon‐free regimens. Until these new treatments are released, the decision to treat patients with HCV genotype 2 with currently approved drugs or to wait for future options must be made, taking into account the stage of fibrosis.

[1]  P. Chen,et al.  FINAL RESULTS OF ENABLE 1, A PHASE 3, MULTICENTER STUDY OF ELTROMBOPAG AS AN ADJUNCT FOR ANTIVIRAL TREATMENT OF HEPATITIS C VIRUS-RELATED CHRONIC LIVER DISEASE ASSOCIATED WITH THROMBOCYTOPENIA , 2011 .

[2]  S. Zeuzem,et al.  Management of Hepatitis C virus Genotype 2 or 3 Infection: Treatment Optimization on the Basis of Virological Response , 2009, Antiviral therapy.

[3]  A. Andriulli,et al.  Short-term treatment duration for HCV-2 and HCV-3 infected patients. , 2006, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[4]  M. Buti,et al.  A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[5]  S. Sarin,et al.  Treatment of patients with genotype 3 chronic hepatitis C‐ current and future therapies , 2012, Liver international : official journal of the International Association for the Study of the Liver.

[6]  K. Shianna,et al.  An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. , 2010, Gastroenterology.

[7]  G. Dore,et al.  1418 DACLATASVIR COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN FOR 12 OR 16 WEEKS IN PATIENTS WITH HCV GENOTYPE 2 OR 3 INFECTION: COMMAND GT2/3 STUDY , 2013 .

[8]  M. Ghany,et al.  Diagnosis, management, and treatment of hepatitis C: An update , 2009, Hepatology.

[9]  John McNally,et al.  Sofosbuvir for previously untreated chronic hepatitis C infection. , 2013, The New England journal of medicine.

[10]  T. Asselah,et al.  Genomics and HCV infection: progression of fibrosis and treatment response. , 2012, Journal of hepatology.

[11]  A. Aghemo,et al.  How to optimize HCV therapy in genotype 2 patients , 2013, Liver international : official journal of the International Association for the Study of the Liver.

[12]  B. Bacon,et al.  Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. , 2007, The New England journal of medicine.

[13]  F. Negro,et al.  Trends and projections of hepatitis C virus epidemiology in Latin America , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[14]  N. Afdhal,et al.  Use of growth factors with antiviral therapy for chronic hepatitis C. , 2005, Clinics in liver disease.

[15]  S. Zeuzem,et al.  EASL Clinical Practice Guidelines: management of hepatitis C virus infection. , 2011, Journal of hepatology.

[16]  P. Marcellin,et al.  High sustained virologic response rates in rapid virologic response patients in the large real‐world PROPHESYS cohort confirm results from randomized clinical trials , 2012, Hepatology.

[17]  A. Andriulli,et al.  Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. , 2005, The New England journal of medicine.

[18]  J. Havens,et al.  Hepatitis C viremia and genotype distribution among a sample of nonmedical prescription drug users exposed to HCV in rural Appalachia , 2012, Journal of medical virology.

[19]  T. Asselah,et al.  Interferon free therapy with direct acting antivirals for HCV , 2013, Liver international : official journal of the International Association for the Study of the Liver.

[20]  A. Mangia,et al.  What's new in HCV genotype 2 treatment , 2012, Liver international : official journal of the International Association for the Study of the Liver.

[21]  K. Kowdley,et al.  61 TREATMENT WITH SOFOSBUVIR + RIBAVIRIN FOR 12 WEEKS ACHIEVES SVR12 OF 78% IN GT2/3 INTERFERON-INELIGIBLE, -INTOLERANT, OR -UNWILLING PATIENTS: RESULTS OF THE PHASE 3 POSITRON TRIAL , 2013 .

[22]  M. Dumont,et al.  European Association for the Study of the Liver , 1971 .

[23]  J. Lee,et al.  Prevalence of Hepatitis C Virus Infections and Distribution of Hepatitis C Virus Genotypes among Korean Blood Donors , 2012, Annals of laboratory medicine.

[24]  S. Erensoy,et al.  Distribution of hepatitis C virus genotypes in patients with chronic hepatitis C infection in Western Turkey. , 2008, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.